Camila Camacho-Navas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Camila Camacho-Navas has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Anmol Nayak
Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, KY, 40536
1 shared publicationAnwesha Goswami
Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, KY, 40536
1 shared publication- David W. Rodgers
Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, KY, 40536
1 shared publication - Emilia Galperin
Department of Molecular and Cellular Biochemistry University of Kentucky Lexington Kentucky USA
1 shared publication Eun Suk Song
Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, KY, 40536
1 shared publicationJing Chen
Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, KY, 40536
1 shared publication
Latest Publications
- 26 September 2026
- Published by Springer Nature
- p. 813-826
Temporal Dynamics of Physiological Responses to Phasic Pain in Healthy Controls and Their Impact on Machine Learning-Based Pain Quantification
- 26 September 2026
- Published by Springer Nature
- p. 813-826
Temporal Dynamics of Physiological Responses to Phasic Pain in Healthy Controls and Their Impact on Machine Learning-Based Pain Quantification
- Open Access
Insulin-degrading enzyme activity is modulated by interaction with pyrroline-5-carboxylate reductase 1
Insulin-degrading enzyme (IDE, insulysin, insulinase) is a peptidase that hydrolyzes a number of bioactive peptides including insulin and the amyloid beta peptide, making it a promising therapeutic target for diabetes and Alzheimer’s disease. Aspects of its physiological role are still controversial, however. In an attempt to further define IDE’s role in cells, we used co-immunoprecipitation experiments to identify potential IDE interacting proteins. The enzyme pyrroline-5-carboxylate reductase 1 (PYCR1) was found associated with IDE in three different cell lines, and the two proteins colocalize in HeLa cells. Purified PYCR1 activates IDE toward small peptide substrates, suggesting a modulatory role for the interaction in vivo . Modeling suggests that the unstructured N-terminal region of PYCR1 inserts into allosteric sites of IDE, contributing to the observed activation. Deleting this sequence alters, but does eliminate, the interaction between PYCR1 and IDE. Since pyrroline-5-carboxylate reductase 1 is a mitochondrial protein, we posit that their interaction could regulate a previously described mitochondrial pool of IDE, which may serve to degrade mitochondrial targeting sequences or amyloid beta peptide that localizes to that organelle.
Open AccessInsulin-degrading enzyme activity is modulated by interaction with pyrroline-5-carboxylate reductase 1
Insulin-degrading enzyme (IDE, insulysin, insulinase) is a peptidase that hydrolyzes a number of bioactive peptides including insulin and the amyloid beta peptide, making it a promising therapeutic target for diabetes and Alzheimer’s disease. Aspects of its physiological role are still controversial, however. In an attempt to further define IDE’s role in cells, we used co-immunoprecipitation experiments to identify potential IDE interacting proteins. The enzyme pyrroline-5-carboxylate reductase 1 (PYCR1) was found associated with IDE in three different cell lines, and the two proteins colocalize in HeLa cells. Purified PYCR1 activates IDE toward small peptide substrates, suggesting a modulatory role for the interaction in vivo . Modeling suggests that the unstructured N-terminal region of PYCR1 inserts into allosteric sites of IDE, contributing to the observed activation. Deleting this sequence alters, but does eliminate, the interaction between PYCR1 and IDE. Since pyrroline-5-carboxylate reductase 1 is a mitochondrial protein, we posit that their interaction could regulate a previously described mitochondrial pool of IDE, which may serve to degrade mitochondrial targeting sequences or amyloid beta peptide that localizes to that organelle.